Inclusion Criteria:  • Histologically confirmed infiltrating breast cancer  Stage II or stage III disease. Nodal status must be examined by ultrasound, fine needle aspiration, sentinel node biopsy, or FDG-PET scan. Age ≥18 Eastern Cooperative Oncology Group performance status ≤1 Adequate bone marrow function (ANC >1.5 x 109/l, platelets >100 x 109/l) Adequate hepatic function (ALAT, ASAT and bilirubin <2.5 times upper limit of normal) Adequate renal function (creatinine clearance >50 ml/min) LVEF ≥50% measured by echocardiography or MUGA Absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule Absence of any medical condition that would place the patient at unusual risk. Signed written informed consent  Exclusion Criteria:  • previous radiation therapy or chemotherapy  Other malignancy except carcinoma in situ, unless the other malignancy was treated ≥5 years ago with curative intent without the use of chemotherapy or radiation therapy. Current pregnancy or breastfeeding. Women of childbearing potential must use adequate contraceptive protection. Evidence of distant metastases. Evaluation of the presence of distant metastases may include chest X-ray, liver ultrasound, isotope bone-scan, CT-scan of chest and abdomen and/or FDG-PET scan, according to local procedures. Evidence of bilateral infiltrating breast cancer. Evaluation of the presence of bilateral infiltrating breast cancer may include mammography, breast ultrasound and/or MRI breast. Concurrent anti-cancer treatment or another investigational drug.